Boston Scientific Corporation (BSX)

NYSE: BSX · USD

$42.1

-2.96 (-6.6%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-22

Our latest published analysis: BSX rated Strong Buy

Boston Scientific Corporation's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$65.9 / share

Potential value

$85.8 / share

Upside to FV

+48.1%

from $42.1

Moat

8/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$64.5B
Revenue (ttm)	21.1B
Net income (ttm)	3.5B
EPS (ttm)	$2.37
Shares out	1.4B
P/E (trailing)	17.8x
P/E (forward)	13.2x
Volume	66,508,095
Beta	0.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 21.1B
Net income (ttm): 3.5B
EPS (ttm): $2.37
P/E (trailing): 17.8x
P/E (forward): 13.2x
Market cap: $64.5B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$11.89B	$12.68B	$14.24B	$16.75B	$20.07B	+14.0%
Gross profit	$8.18B	$8.73B	$9.90B	$11.49B	$13.85B	+14.1%
Operating income	$1.20B	$1.65B	$2.34B	$2.60B	$3.61B	+31.8%
Net income	$1.04B	$698.0M	$1.59B	$1.85B	$2.89B	+29.1%
EPS (diluted)	$0.69	$0.45	$1.07	$1.25	$1.94	+29.5%
EBITDA	$2.52B	$2.74B	$3.45B	$3.94B	$5.10B	+19.3%
R&D	$1.20B	$1.32B	$1.41B	$1.62B	$2.05B	+14.3%
SG&A	$4.36B	$4.52B	$5.19B	$5.98B	$6.89B	+12.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Bull20%

Price target

$85.81

+92.8% from spot

In the bull case, rapid clinical adoption of pulsed field ablation in international territories outpaces expectations, while FARAPULSE Ultra and ICE achieve broad commercial availability ahead of schedule in early 2027. Standalone WATCHMAN volume contraction reverses quickly as clinical education programs and 3-year CHAMPION trial data reassure physicians,. Annual diluted EPS growth reaches 14.5% to 15.0%, and operating margins expand toward top-tier peer levels.

Annual EPS growth accelerates to 14.5% - 15.0% across the forecast period.
Rapid European and Asian PFA adoption alongside early 2027 introduction of FARAPULSE Ultra and ICE,.
Rapid realization of $500M efficiency savings driving operating margins toward 30.0%.

Base55%

Price target

$65.94

+48.1% from spot

The base case models management's updated FY2026 organic revenue guidance of 5% to 6% and consensus EPS of $3.24. In FY2027, revenue advances 4.85% with EPS of $3.38 as product mix headwinds linger and Penumbra is integrated. Commencing in FY2028, revenue growth accelerates to 7.5% and operating margins reach 28.5% by FY2030 as FARAPULSE Ultra scales and $500M in efficiency savings are realized,.

Revenue growth of 5.41% in FY2026, 4.85% in FY2027, 7.5% in FY2028, and 6.0% in FY2030.
Operating margin expanding from 26.5% in FY2026 to 28.5% in FY2030.
Cost of equity of 8.0211% and terminal growth rate of 3.0%,.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($65.94). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	2.8%	3.0%	3.3%	3.5%
7.0%	$73.0	$75.7	$78.6	$82.0	$85.9
7.5%	$67.2	$69.3	$71.6	$74.2	$77.1
8.0%	$62.5	$64.1	$65.9	$68.0	$70.2
8.5%	$58.5	$59.8	$61.3	$62.9	$64.7
9.0%	$55.1	$56.2	$57.4	$58.7	$60.1

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.2

P25 n/aP50 n/aP75 n/a

Trailing P/E18.5

P25 n/aP50 n/aP75 n/a

ROE15.3

P25 n/aP50 n/aP75 n/a

ROIC11.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BSX indicators

Market & fundamental data

Available fields

268

Groups with data

Currency

USD

Showing 268 of 268 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000885725
Company name	Boston Scientific Corporation
Country	United States
Country code	US
CUSIP number	101137107
Earnings date	2026-10-28
Earnings time	bmo
Employees	59,000
Employees change	6,000
Employees growth	11.32%
Enterprise value	$73.1B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1979
In index	SP500
Industry	Medical Devices
IPO date	1992-05-18
Is primary listing	Yes
Is SPAC	No
ISIN number	US1011371077
Last 10-K release date	2026-02-17
Last earnings date	2026-10-28
Last refreshed	2026-10-28
Last stock split date	2003-11-06
Last stock split type	Forward
Market cap	$61B
Market cap category	Large-Cap
Next earnings date	2027-02-03
Options	Yes
Price	$42.11
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	BSX
U.S. state	Massachusetts
Website	https://www.bostonscientific.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	13.2x
Average P/E ratio (10Y)	76.84x
Average P/E ratio (3Y)	50.98x
Average P/E ratio (5Y)	62.9x
Earnings yield	5.62%
EV/Earnings	21.35x
EV/EBIT	17.23x
EV/EBITDA	12.96x
EV/FCF	20.62x
EV/Sales	3.55x
FCF / EV yield	4.85%
FCF yield	5.78%
Forward EV/Sales	3.43x
Forward P/E	12.73x
Forward P/S	2.88x
Graham number	30.30021
Graham upside	-29.94%
Industry forward P/E	19.81x
Industry P/E	39.28x
Lynch fair value	$59.20
Lynch upside	36.87%
P/(FCF - SBC) ratio	18.96x
P/(OCF - SBC) ratio	14.89x
P/B ratio	2.61x
P/E ratio	17.78x
P/FCF ratio	17.29x
P/OCF ratio	13.84x
P/S ratio	2.97x
PEG ratio	1.02x
Price/EBITDA ratio	10.86x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	20.6%
EBITDA margin	27.38%
Effective tax rate	4.43%
FCF margin	17.27%
Gross margin	68.94%
Operating margin	20.6%
Pretax margin	17.35%
Profit margin	16.62%
Profit per employee	$59,356
Profitable quarters	23
Profitable years	5
Revenue per employee	$357,119
ROA	6.19%
ROA (5Y)	4.61%
ROCE	11.08%
ROE	15.34%
ROE (5Y)	8.1%
ROIC	11.13%
ROIC (5Y)	7.52%
SBC / revenue	1.52%
Tax / revenue	0.77%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	26.63%
EPS growth (Q)	-21.5%
EPS growth (QoQ)	-34.43%
EPS growth 10Y	46.25%
EPS growth 3Y	42.32%
EPS growth 5Y	25.24%
EPS growth quarters	7
EPS growth years	3
FCF growth	4.02%
FCF growth 3Y	33.93%
FCF growth 5Y	14.35%
Gross profit growth	8.88%
Gross profit growth (Q)	-3.23%
Gross profit growth 3Y	15.2%
Gross profit growth 5Y	12.47%
Net income growth	25.48%
Net income growth (Q)	-22.91%
Net income growth (QoQ)	-35.83%
Net income growth 3Y	43.26%
Net income growth 5Y	26.04%
Net income growth quarters	7
Net income growth years	3
OCF growth	5.69%
OCF growth 10Y	13.52%
OCF growth 3Y	28.69%
OCF growth 5Y	15.09%
Operating income growth	13.05%
Operating income growth (Q)	-6.76%
Operating income growth 3Y	23.11%
Operating income growth 5Y	17.01%
Revenue growth	8.89%
Revenue growth (Q)	1.44%
Revenue growth (QoQ)	-5.59%
Revenue growth 10Y	10.04%
Revenue growth 3Y	15.27%
Revenue growth 5Y	12.93%
Revenue growth quarters	22
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-904M
Depreciation and amortization	$1.4B
EBIT	$4.3B
EBITDA	$5.8B
EPS	$2.37
FCF per share	$2.50
Financing cash flow	$-958M
Free cash flow	$3.6B
Free cash flow minus SBC	$3.3B
Gross profit	$14.5B
Income taxes	$162M
Investing cash flow	$-3.6B
Net borrowing	$978M
Net cash flow	$12M
Net income	$3.5B
Operating cash flow minus SBC	$4.2B
Operating income	$4.3B
Revenue	$21.1B
Stock-based compensation	$320M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$17.23
Debt / EBITDA	2.17
Debt / equity	0.5
Debt / FCF	3.48
Interest coverage	11.57
Net cash (debt)	$-12.1B
Net cash / market cap	-19.28%
Net debt / EBITDA	2.09
Net debt / equity	0.48
Net debt / FCF	3.33
Piotroski F-Score	5
Shareholders' equity	$25.2B
Tangible book value	$-628M
Tangible book value per share	$-0.43
Total cash	$539M
Total debt	$12.6B
WACC	6.65%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.48
Current ratio	1.24
Inventory turnover	2.12
Quick ratio	0.56
Working capital	$1.5B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.91%
Dividend yield	0%
Shareholder yield	0.91%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	101.49%
10Y return CAGR	7.26%
10Y total return	101.49%
150-day SMA	$49.81
15Y price change	671.84%
15Y return CAGR	14.6%
15Y total return	671.84%
1D price change	-6.56%
1M price change	-1.41%
1M total return	-1.41%
1W price change	-5%
1W total return	-5%
1Y price change	-57.73%
1Y return CAGR	-57.75%
1Y total return	-57.73%
20-day SMA	$43.81
200-day SMA	$57.04
20Y price change	169.78%
20Y return CAGR	5.09%
20Y total return	169.78%
3M price change	-4.86%
3M total return	-4.86%
3Y price change	-12.56%
3Y return CAGR	-4.37%
3Y total return	-12.56%
50-day SMA	$45.15
50-day SMA vs 200-day SMA	50under200
52-week high	$105.65
52-week high date	2025-11-13
52-week low	$39.57
52-week low date	2026-10-28
5Y price change	-0.98%
5Y return CAGR	-0.2%
5Y total return	-0.98%
6M price change	-27.77%
6M total return	-27.77%
After-hours change	0.76%
After-hours close	$42.11
After-hours price	$42.43
All-time high	$109.50
All-time high date	2025-09-09
All-time low	$2.34
All-time low date	1993-10-07
Average true range (ATR)	$1.51
Average volume	16.4M
Beta (1Y)	0.43
Beta (2Y)	0.72
Beta (5Y)	0.58
Change from 52-week high	-60.15%
Change from 52-week low	6.41%
Change from all-time high	-60.46%
Change from all-time low	1,747.27%
Change from open	0.01%
Day's gap	-6.57%
Dollar volume	$2.8B
High price	$43.91
Low price	$39.60
Monthly RSI	27.7
Open price	$42.10
Position in 52-week range	58.12%
Premarket change	-8.34%
Premarket close	$45.06
Premarket price	$41.30
Premarket volume	4.7M
Previous close	$45.06
Price vs 150-day SMA	-13.06%
Price vs 20-day SMA	-1.17%
Price vs 200-day SMA	-24.08%
Price vs 50-day SMA	-4.09%
Relative volume	4.07
RSI	43.68
Sharpe ratio	-2.14
Sharpe ratio (3Y)	-0.17
Sharpe ratio (5Y)	-0.03
Sortino ratio	-2.39
Sortino ratio (3Y)	-0.04
Sortino ratio (5Y)	0.15
Volume	66.5M
Weekly RSI	35.01
YTD price change	-54.59%
YTD total return	-54.59%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.4B
Float percentage	99.71%
Shares change (QoQ)	-1.55%
Shares change (YoY)	-0.91%
Shares held by insiders	0.18%
Shares held by institutions	93.2%
Shares outstanding	1.4B
Short % of float	2.87%
Short % of shares	2.86%
Short ratio	2 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	1,293

Deeper analysis on BSX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this BSX report

What is the latest published BSX stock rating?

Boston Scientific Corporation is shown with Strong Buy in the latest published report, analyzed 2026-10-22. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BSX analysis?

The full latest published report, analyzed 2026-10-22, lives at /stocks/BSX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for BSX?

The latest published report analyzed 2026-10-22 gives BSX a fair value of USD 66 and a potential value of USD 86. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the BSX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-22). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Strong BuyBSX · Fair value $65.9+48.1%

Read full analysis →

Boston Scientific Corporation (BSX)

Our latest published analysis: BSX rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · BSX

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All BSX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on BSX

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	8.5
Management	8.5
Balance Sheet	6.0
Profitability	6.5
Revenue Growth	6.0
Risk Assessment	7.5
Competitive Moat	8.0
Earnings Quality	8.0
Capital Efficiency	5.5